E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
GTX  
GTX
GTXILast: $3.40 ($+0.02)Volume: 34,001Last Trade: 8/5/2010 5:20:01 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NASDAQ:GTXI $3.40 ($+0.02 +0.5917%)
Industry: Health Sector: Pharmaceuticals
Open: 3.38 Previous Close: 3.38
Day's High: 3.40 Day's Low: 3.33
52-Week High: 23.64 52-Week Low: 10.75
 
Bid: 3.39 / 100 Ask: 3.40 / 700
Volume: 34,001 Outstanding: 34,922,124
Market Cap: $496 M
GTX Profile
GTx is a biopharmaceutical company which discovers, develops and commercializes small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. Co. develops ACAPODENE (toremifene citrate), a selective estrogen receptor modulator, in two separate clinical programs in men: a Phase III clinical trial for the treatment of multiple serious side effects of androgen deprivation therapy (ADT), for advanced prostate cancer; and a Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN).
 GTX News & Press Releases

GTx Announces Upcoming ASCO Presentations of Additional Study Results from Clinical Trials Evaluatin
GTx Inc. ( GTXI ) today announced that additional study results from clinical trials evaluating Ostarine™ (GTx-024) for the treatment of cancer cachexia and to... [more]



GTx and Ipsen Expand Partnership
Regulatory News: Ipsen (Paris:IPN)(Euronext: FR0010259150; IPN) and GTx, Inc. ( GTXI ) today announced the expansion of their partnership for the de... [more]

GTx Announces Reduction in Force
GTx, Inc. ( GTXI ) today announced a reduction in force reflecting the delay in the potential commercialization of toremifene 80 mg to reduce fractures in men... [more]

GTx to Host Conference Call and Webcast to Provide Update on Status of Toremifene 80 mg New Drug App
GTx, Inc. ( GTXI ) today announced that it will host a conference call and webcast on Monday, November 2, 2009 to provide an update regarding the New Drug Appl... [more]

GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety
GTx, Inc. ( GTXI ), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company... [more]

GTx Announces Presentation of Toremifene 80 mg Data at Fourth Annual Chicago Supportive Oncology Con
GTx, Inc. ( GTXI ) announced that data from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of estrogen deficiency side effects of a... [more]

GTx Announces Phase III PIN Clinical Trial Will Continue As Planned
GTx, Inc. ( GTXI ) today announced that an independent biometrics group recommended that the Phase III clinical trial evaluating toremifene 20 mg in men with h... [more]

GTx Announces Webcast of Corporate Presentation at the Lehman ...
PR-Inside.com (Pressemitteilung): GTx Announces Webcast of Corporate Presentation at the Lehman ... , Austria - Mar 16, 2008 www.gtxinc.com - GTx, Inc. ( Nasdaq: GTXI ) announced today that management will present a company overview at the Lehman Brothers Global Health

GTx Announces Webcast of Corporate Presentation at the 28th Annual ...
Ad-Hoc-News (Pressemitteilung): GTx Announces Webcast of Corporate Presentation at the 28th Annual ... , Germany - Mar 10, 2008 GTx, Inc. ( Nasdaq: GTXI ) announced today that management will present a company overview at the 28 th Annual Cowen and Company Health Car

GTx Announces Webcast of Corporate Presentation at the 28 th ...
Business Wire (press release): GTx, Inc. ( Nasdaq: GTXI ) announced today that management will present a company overview at the 28 th Annual Cowen and Company Health Care ...

GTx Announces Additional Top Line Phase III Data Demonstrating ...
Lifescience-online: GTx Announces Additional Top Line Phase III Data Demonstrating ... , Switzerland - Mar 3, 2008 GTx, Inc. ( NASDAQ: GTXI ) today announced that toremifene citrate 80 mg reduced hot flashes in men with prostate cancer on androgen depriva

GTx Study Shows Positive Results In Reducing Prostate Cancer ...
Trading Markets (press release): GTXI | news | PowerRating | PR Charts -- March 3, 2008 (FinancialWire) GTx Inc. ( NASDAQ: GTXI | news | PowerRating | PR ...

GTX, Inc. Reports First Quarter 2007 Financial Results
American Digital Networks (press release): , MD - May 4, 2007 Business Wire)-May 4, 2007 - GTx, Inc. ( Nasdaq: GTXI ) today reported financial results for the first quarter of 2007. The net loss for the quarter ended ...

CybeRelease: (OTC: GNLM) Up 13% on Today’s Trading
WebWire (press release): , GA - Apr 30, 2007 ... Inc. (Nasdaq: BLTI), Sigmatel, Inc. (Nasdaq: SGTL), GenVec, Inc. (Nasdaq: GNVC), GTx, Inc. ( Nasdaq: GTXI ) and Mobility Electronics, Inc. (Nasdaq: MOBE). ...

GTx, Inc. Announces First Quarter 2007 Financial Results ...
Therapeutics Daily (subscription) (press release): Apr 20, 2007 - GTx, Inc. ( Nasdaq: GTXI ), today announced that it will host a conference call and webcast to discuss the Company's first ...

GTx Announces Ostarine(TM) Improved Insulin Resistance among ...
PipelineReview.com (press release): GTx Announces Ostarine(TM) Improved Insulin Resistance among ... , Spain - Apr 17, 2007 GTx, Inc. ( NASDAQ: GTXI ) announced today that data from a recently conducted Phase II Ostarine(TM) clinical trial of 60 elderly men and 60 postme

GTx Announces Ostarine Improved Insulin Resistance among Elderly ...
PharmaLive.com (press release): Apr 17, 2007 - GTx, Inc. ( NASDAQ: GTXI ) announced today that data from a recently conducted Phase II Ostarine(TM) clinical trial of 60 ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts